Twist Bioscience Corporation stock surged 16.1% to close at $184.03 on September 24 — a violent gap-driven repricing from an open of $157.72. The trend is undeniably powerful. Yet overextension risk now sits squarely alongside it.
Key takeaways
- TWST closed at $184.03 on September 24, gaining 16.1% in a gap-driven session from a prior close of $158.50.
- Daily RSI14 hit 74.39 — firmly overbought — while price closed above the upper Bollinger Band at $177.20.
- The Lilly TuneLab partnership, announced September 16, provides the fundamental catalyst behind the rally.
- All three timeframes show bullish EMA stacking but also RSI overbought readings on the daily, hourly, and 15-minute charts.
- Key levels to watch: daily pivot at $175.36 and S1 support at $165.50.
Twist Bioscience Corporation Stock Daily Trend: Stretched to Extremes
The daily chart for Twist Bioscience Corporation stock is unambiguously bullish. Price sits well above every major moving average. The EMA20 reads147.51, the EMA50 sits at128.44, and the EMA200 is far below at83.93. Each shorter-term average stands above the longer ones — a textbook bullish regime.
Momentum, however, confirms the trend while also flagging risk. Daily RSI14 stands at74.39, comfortably inside overbought territory. The MACD remains bullish, with the line at12.17 above the signal at8.83 and a positive histogram of3.34. Buyers are firmly in control, but the magnitude suggests the move has run hot rather than simply trending.
Volatility tells the same story from a different angle. Daily Bollinger Bands show a midline of143.45 with an upper band at177.20. Notably, Thursday’s close sits entirely above the upper band — a classic sign of a breakout that has outrun its own volatility envelope. Meanwhile, ATR14 at11.28 confirms daily ranges have widened sharply. Both the upside and any reversal could move fast.
Pivot levels reinforce the bullish session. The pivot point sits at175.36, with R1 resistance at 193.89 and S1 support at 165.50. Price closing well clear of the pivot underscores that bulls dictated terms throughout the session.
Hourly Timeframe: Confirmation With a Caveat
The hourly chart broadly confirms the daily bullish bias. The EMA20 at169.86, EMA50 at161.04, and EMA200 at140.54 are all stacked in bullish order beneath current price. The regime reading again flags bullish conditions. However, RSI14 on the hourly sits at71.89 — still overbought but slightly cooler than the daily reading of74.39.
Hourly MACD remains constructive, with the line at5.34 above the signal at3.62 and a histogram of1.72. In contrast, the histogram here is smaller in absolute terms than on the daily. This hints that intraday momentum, while still positive, is decelerating relative to the broader trend.
The hourly Bollinger setup reveals the caveat most clearly. The upper band sits at 184.20, and the latest hourly close of184.03 presses almost exactly against it. In other words, the hourly chart tests its own volatility ceiling. This position often precedes either a fresh acceleration or a short-term pause. Hourly ATR14 of5.19 confirms intraday swings remain wide, consistent with a market still expanding.
15-Minute Chart: Execution Context Only
On the15-minute timeframe, conditions mirror the higher timeframes closely. RSI14 reads74.65, while the MACD histogram is a modest0.50. The EMA20 at176.87, EMA50 at171.39, and EMA200 at159.37 are all stacked bullishly. Price again tests the upper Bollinger Band at 184.69, just above the last close.
Meanwhile, the15-minute pivot structure is tight: pivot at184.15, R1 at185.10, and S1 at183.09. This narrow range reflects where the market consolidates immediately after the gap. It should be read as short-term timing context rather than a directional signal in its own right.
The News Backdrop: Lilly TuneLab Catalyst
A fundamental catalyst underpins the rally. On September 16, Twist Bioscience confirmed a partnership with Lilly TuneLab, a platform created by Eli Lilly. The deal gives TWST expanded exposure to the AI-driven drug discovery ecosystem. This kind of strategic tie-up helps explain why buyers stepped in aggressively.
Separate coverage noted that TWST has surged 493% over the past 52 weeks and just hit a new all-time high. It carries a 100% “Buy” technical opinion. However, the same reporting flagged an RSI of 72.95 and elevated short interest as signals of potential overextension. Consensus analyst price targets also sit well below the current share price. That gap between where TWST trades and where analysts see fair value is worth keeping in mind.
Bullish Scenario: Trend Continuation Above $175.36
The bullish case for Twist Bioscience Corporation stock rests on trend continuation. If price holds above the daily pivot at $175.36 and clears R1 near $193.89, the EMA structure across all three timeframes supports further upside. The Lilly TuneLab deal, combined with a fully bullish technical regime, gives momentum traders a coherent story to follow. For this scenario to strengthen, volume must stay elevated and the daily close must hold above the upper Bollinger Band rather than snapping back inside it.
Bearish Scenario: Exhaustion Risks at Overbought Extremes
On the other hand, the corrective case centers on exhaustion. Daily RSI above 74 and price trading above its own upper Bollinger Band frequently precede a pullback or sideways digestion. A daily close back below the pivot at $175.36 would invalidate the immediate bullish continuation thesis. The same applies to a break of S1 at $165.50. Meanwhile, the hourly chart’s slowing MACD histogram and its close at the upper band suggest a short-term stall is already plausible. This holds even if the broader daily trend stays intact. Elevated short interest also raises the possibility of sharp two-way volatility if sentiment shifts.
Closing Thoughts
Overall, Twist Bioscience Corporation stock is in a genuinely powerful uptrend. Yet it has moved far enough and fast enough to demand caution alongside conviction. Daily and hourly structure both confirm bullish control. However, overbought RSI readings across every timeframe and a daily close above the upper Bollinger Band point to a market running ahead of its own volatility. Therefore, positioning likely calls for tighter risk management rather than chasing extension. The daily pivot and S1 levels serve as practical reference points for how the current trend holds up. Given elevated ATR readings on both daily and hourly charts, sharp moves in either direction should not surprise in the sessions ahead.
FAQ
Why did Twist Bioscience Corporation stock surge on September 24?
The16.1% surge to $184.03 was driven by bullish momentum following the September16 announcement of a partnership with Lilly TuneLab, an Eli Lilly platform focused on AI-driven drug discovery. The stock also carried a100% “Buy” technical opinion and had already gained493% over the prior52 weeks.
Is TWST overbought after the September24 rally?
Yes. Daily RSI14 reached74.39 — firmly in overbought territory — and price closed above the upper Bollinger Band at $177.20. Hourly RSI14 at71.89 and15-minute RSI14 at74.65 confirm overbought conditions across all timeframes, suggesting the rally has run ahead of its own volatility.
What are the key support levels for Twist Bioscience Corporation stock?
The daily pivot at $175.36 serves as the first key reference point. A break below S1 at $165.50 would invalidate the immediate bullish continuation thesis. The daily EMA20 at147.51 offers deeper structural support.
What is the bullish price target for TWST?
If price holds above the daily pivot at $175.36 and clears R1 resistance near $193.89, the bullish EMA structure across daily, hourly, and15-minute timeframes supports further upside continuation.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument or cryptocurrency. The analysis provided is not indicative of future results. Investing in crypto assets and financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.